Eli Lilly & Co. (NYSE:LLY)
The Company discovers, develops, manufactures and sells products in one of its business segment of pharmaceutical products to prevent and treat human diseases.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
Has to be the worst of breed pharma.
Recs
Value and dividend
Recs
Diabetes will be around a long time and so will Lilly.
Recs
http://seekingalpha.com/article/976681-steven-cohen-s-10-favorite-dividend-stock-picks
Recs
Surprising success in Alzheimer's portfolio
Recs
Over exuberance for Alzheimer's program.
Recs
They are the heart and soul of indianapolis. This company does great things for the state of Indiana and health care!
Recs
Eli Lilly Company is one of the premier BIG PHARMA companies based in Indianopolis, IN. With the new Obama Health care moving by phases into effect, Health Insurance Coverage will be near Universal in the United States. Demand for Health Services will be fueled by the newly covered population. With Universal coverage, of course comes Government Price Controls.
Many Physicians and other Healthcare providers Opted-out of Medicare in 2011 more will opt-out in 2012. Once a Healthcare provider opts-out they can NOT return and get back-into Medicare or Medicade. They opt-out, of course, to control their own business practice of Medicine. That practice Business decision comes with it a diminished available market.
Sobeit say the providers who opt-out. Let them pound sand will say the patients.
WHOVenturePartners, LLC
Kailua-Kona 96745
Recs
cap spending ahead
Recs
A fossilized company that will unfortunately go the way of dinosaurs. They have a major patent gap on them and I do not see how they can overcome with "same old" corporate culture. This one is cooked.
Recs
veternary products; retained corporate brainpower
Recs
Dividend rockstar, most numbers are good. Probably make this one 1%.
Recs
Undervalued. Target ~50$.
Recs
Long this. Gorgeous value stock with great dividend. I got in a few months ago. Get in the next time a drug misses approval.
Recs
Recs
Falling off the patent cliff but the metrics look outstanding. A great time to buy in. Company has been around since 1901. I doubt they will go under just because of a few patent expirations. Currently yielding 5%. p/e=8.5, payout ratio=43%, beta= 0.67.
Buy Buy Buy!
Recs
Possible Alzhiemer drug in the works and a nice dividend.
Recs
Promising drugs in the pipeline...
Recs
Recs
fundamentals look very goog
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 196 : 1 2 3 4 5 6 7 8 9 10 Next »